Swiss Life Asset Management Ltd Has $22.38 Million Stock Position in Zoetis Inc. $ZTS

Swiss Life Asset Management Ltd grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 22.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 177,893 shares of the company’s stock after acquiring an additional 32,202 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Zoetis were worth $22,382,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. RFG Advisory LLC boosted its position in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after acquiring an additional 80 shares during the last quarter. YANKCOM Partnership boosted its position in Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after acquiring an additional 81 shares during the last quarter. Evergreen Capital Management LLC raised its stake in shares of Zoetis by 3.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after purchasing an additional 85 shares in the last quarter. Beese Fulmer Investment Management Inc. raised its stake in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares in the last quarter. Finally, Quest 10 Wealth Builders Inc. raised its stake in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 7.5%

ZTS opened at $76.62 on Tuesday. Zoetis Inc. has a 1-year low of $76.38 and a 1-year high of $172.23. The stock’s fifty day simple moving average is $116.50 and its 200 day simple moving average is $122.77. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a market cap of $32.12 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the company posted $1.48 EPS. The firm’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ZTS shares. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Citigroup started coverage on Zoetis in a research note on Wednesday, April 15th. They set a “buy” rating and a $145.00 price objective on the stock. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Finally, UBS Group dropped their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $141.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.